These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 33601323)
1. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323 [TBL] [Abstract][Full Text] [Related]
2. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153 [TBL] [Abstract][Full Text] [Related]
3. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Pearson ADJ; Rossig C; Lesa G; Diede SJ; Weiner S; Anderson J; Gray J; Geoerger B; Minard-Colin V; Marshall LV; Smith M; Sondel P; Bajars M; Baldazzi C; Barry E; Blackman S; Blanc P; Capdeville R; Caron H; Cole PD; Jiménez JC; Demolis P; Donoghue M; Elgadi M; Gajewski T; Galluzzo S; Ilaria R; Jenkner A; Karres D; Kieran M; Ligas F; Lowy I; Meyers M; Oprea C; Peddareddigari VGR; Sterba J; Stockman PK; Suenaert P; Tabori U; van Tilburg C; Yancey T; Weigel B; Norga K; Reaman G; Vassal G Eur J Cancer; 2020 Mar; 127():52-66. PubMed ID: 31986450 [TBL] [Abstract][Full Text] [Related]
4. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944 [TBL] [Abstract][Full Text] [Related]
5. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Pearson ADJ; Federico S; Gatz SA; Ortiz M; Lesa G; Scobie N; Gounaris I; Weiner SL; Weigel B; Unger TJ; Stewart E; Smith M; Slotkin EK; Reaman G; Pappo A; Nysom K; Norga K; McDonough J; Marshall LV; Ludwinski D; Ligas F; Karres D; Kool M; Horner TJ; Henssen A; Heenen D; Hawkins DS; Gore L; Bender JG; Galluzzo S; Fox E; de Rojas T; Davies BR; Chakrabarti J; Carmichael J; Bradford D; Blanc P; Bernardi R; Benchetrit S; Akindele K; Vassal G Eur J Cancer; 2023 Sep; 190():112950. PubMed ID: 37441939 [TBL] [Abstract][Full Text] [Related]
6. Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Pearson ADJ; Zwaan CM; Kolb EA; Karres D; Guillot J; Kim SY; Marshall L; Tasian SK; Smith M; Cooper T; Adamson PC; Barry E; Benettaib B; Binlich F; Borgman A; Brivio E; Capdeville R; Delgado D; Faller D; Fogelstrand L; Fraenkel PG; Hasle H; Heenen D; Kaspers G; Kieran M; Klusmann JH; Lesa G; Ligas F; Mappa S; Mohamed H; Moore A; Morris J; Nottage K; Reinhardt D; Scobie N; Simko S; Winkler T; Norga K; Reaman G; Vassal G Eur J Cancer; 2020 Sep; 136():116-129. PubMed ID: 32688206 [TBL] [Abstract][Full Text] [Related]
7. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026 [TBL] [Abstract][Full Text] [Related]
9. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer. Pearson AD; DuBois SG; Macy ME; de Rojas T; Donoghue M; Weiner S; Knoderer H; Bernardi R; Buenger V; Canaud G; Cantley L; Chung J; Fox E; Friend J; Glade-Bender J; Gorbatchevsky I; Gore L; Gupta A; Hawkins DS; Juric D; Lang LA; Leach D; Liaw D; Lesa G; Ligas F; Lindberg G; Lindberg W; Ludwinski D; Marshall L; Mazar A; McDonough J; Nysom K; Ours C; Pappo A; Parsons DW; Rosenfeld A; Scobie N; Smith M; Taylor D; Weigel B; Weinstein A; Karres D; Vassal G Eur J Cancer; 2024 Aug; 207():114145. PubMed ID: 38936103 [TBL] [Abstract][Full Text] [Related]
10. Implementation of mechanism of action biology-driven early drug development for children with cancer. Pearson AD; Herold R; Rousseau R; Copland C; Bradley-Garelik B; Binner D; Capdeville R; Caron H; Carleer J; Chesler L; Geoerger B; Kearns P; Marshall LV; Pfister SM; Schleiermacher G; Skolnik J; Spadoni C; Sterba J; van den Berg H; Uttenreuther-Fischer M; Witt O; Norga K; Vassal G; Eur J Cancer; 2016 Jul; 62():124-31. PubMed ID: 27258969 [TBL] [Abstract][Full Text] [Related]
11. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. Pearson ADJ; Scobie N; Norga K; Ligas F; Chiodin D; Burke A; Minard-Colin V; Adamson P; Marshall LV; Balakumaran A; Benettaib B; Bhargava P; Bollard CM; Bolotin E; Bomken S; Buechner J; Burkhardt B; Caron H; Copland C; Demolis P; Egorov A; Farhan M; Zugmaier G; Gross T; Horton-Taylor D; Klapper W; Lesa G; Marcus R; Miles RR; Nottage K; Pacaud L; Ricafort R; Schrappe M; Sterba J; Vezan R; Weiner S; Kim SY; Reaman G; Vassal G Eur J Cancer; 2019 Mar; 110():74-85. PubMed ID: 30772656 [TBL] [Abstract][Full Text] [Related]
12. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734. Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576 [TBL] [Abstract][Full Text] [Related]
13. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Pearson AD; Gaspar N; Janeway K; Campbell-Hewson Q; Lawlor ER; Copland C; Karres D; Norga K; Benzaghou F; Weiner S; Weigel B; Weiss AR; Strauss SJ; Smith M; Setty BA; Seibel N; Scobie N; Pappo A; Okpara CE; Nysom K; McDonough J; Marshall LV; Ludwinski D; Ligas F; Lesa G; Knudsen S; Kauh J; Hsieh A; Heenen D; Hawkins DS; Graham A; Garmey E; DuBois SG; Fox E; Donoghue M; de Rojas T; Chung J; Casanova M; Brennan B; Bishop M; Buenger V; Reaman G; Vassal G Eur J Cancer; 2022 Sep; 173():71-90. PubMed ID: 35863108 [TBL] [Abstract][Full Text] [Related]
14. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Pearson AD; Allen C; Fangusaro J; Hutter C; Witt O; Weiner S; Reaman G; Russo M; Bandopadhayay P; Ahsan S; Barone A; Barry E; de Rojas T; Fisher M; Fox E; Bender JG; Gore L; Hargrave D; Hawkins D; Kreider B; Langseth AJ; Lesa G; Ligas F; Marotti M; Marshall LV; Nasri K; Norga K; Nysom K; Pappo A; Rossato G; Scobie N; Smith M; Stieglitz E; Weigel B; Weinstein A; Viana R; Karres D; Vassal G Eur J Cancer; 2022 Dec; 177():120-142. PubMed ID: 36335782 [TBL] [Abstract][Full Text] [Related]
15. BET inhibitors: a novel epigenetic approach. Doroshow DB; Eder JP; LoRusso PM Ann Oncol; 2017 Aug; 28(8):1776-1787. PubMed ID: 28838216 [TBL] [Abstract][Full Text] [Related]
16. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114 [TBL] [Abstract][Full Text] [Related]
17. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Taniguchi Y Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996 [TBL] [Abstract][Full Text] [Related]
18. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Moreno L; Barone G; DuBois SG; Molenaar J; Fischer M; Schulte J; Eggert A; Schleiermacher G; Speleman F; Chesler L; Geoerger B; Hogarty MD; Irwin MS; Bird N; Blanchard GB; Buckland S; Caron H; Davis S; De Wilde B; Deubzer HE; Dolman E; Eilers M; George RE; George S; Jaroslav Š; Maris JM; Marshall L; Merchant M; Mortimer P; Owens C; Philpott A; Poon E; Shay JW; Tonelli R; Valteau-Couanet D; Vassal G; Park JR; Pearson ADJ Eur J Cancer; 2020 Sep; 136():52-68. PubMed ID: 32653773 [TBL] [Abstract][Full Text] [Related]
19. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924 [TBL] [Abstract][Full Text] [Related]
20. BET Bromodomain as a Target of Epigenetic Therapy. Noguchi-Yachide T Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]